Cytokinetics analyst coverage
WebOur Corporate Responsibility Framework. Keep Patients at the Center of our Work. Continue to embed patient centricity across all stages of our business. Maintain strong … WebMar 7, 2024 · Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Mizuho Posted by Defense World Staff on Mar 7th, 2024 Mizuho assumed coverage on shares of Cytokinetics ( NASDAQ:CYTK – Get...
Cytokinetics analyst coverage
Did you know?
WebSep 28, 2024 · Cytokinetics Incorporated CYTK Competitors News Profile Analyst Coverage 5 Yr. Financials Dividends Adv. Charts Earnings Options Price History Events Insiders Cytokinetics Incorporated News... WebApr 11, 2024 · What analysts cover Cytokinetics? Cytokinetics has been rated by Bank of America, Cantor Fitzgerald, HC Wainwright, JMP Securities, Mizuho, Needham & Company LLC, Oppenheimer, The Goldman Sachs Group, and UBS Group in the past 90 days. Stock Ratings Reports and Tools Top-Rated Brokerages Stock Ratings Screener Free Ratings …
WebMar 31, 2024 · March 31, 2024 Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis. March 27, 2024 Cytokinetics Releases Inaugural Corporate Responsibility Report. March … Web12 hours ago · Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics ( CYTK – Research Report) and Neurocrine ( …
WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media. ... Analyst Coverage. Investor FAQ. IR/Media Contacts. Corporate Governance. Information Request . Email Alerts . WebJul 19, 2024 · SOUTH SAN FRANCISCO, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results …
WebFintel reports that on April 13, 2024, Baird initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with a Outperform recommendation. Analyst Price Forecast Suggests 80.40% Upside As of April 6 ...
WebCYTK Stock 12 Months Forecast. $58.50. (66.24% Upside) Based on 13 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $58.50 with a high forecast of $80.00 and a low forecast of $42.00. The average price target represents a 66.24% change from the last price of $35.19. northern tool generatorWebApr 2, 2024 · Financials. In 2024, Cytokinetics reported revenues of $2.0 million for Q4 and $94.6 million for the full year, compared to $55.6 million and $70.4 million in the same periods of 2024. This ... northern tool gas generatorsWebJul 19, 2024 · The webcast can be accessed through the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by dialing either (866) 999-CYTK (2985) ( United States and Canada ) or (706) 679-3078 (international) and typing in the passcode 2984784. how to run system restore from command lineWeb1 day ago · Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd … northern tool generators for salenorthern tool generator saleWebApr 12, 2024 · Wall Street Analyst Weigh In. Several brokerages recently weighed in on CYTK. Needham & Company LLC reissued a “buy” rating and issued a $58.00 target price on shares of Cytokinetics in a ... how to run system restoreWebMar 31, 2024 · Analyst Coverage; Investor FAQ; IR Contacts; Corporate Governance; Information Request; Email Alerts northern tool generator generator